Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses NT-219: First-In-Class, Novel Small Molecule Designed To Overcome Cancer Drug Resistance.
NT-219: First-In-Class, Novel Small Molecule Designed To Overcome Cancer Drug Resistance
Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses NT-219: First-In-Class, Novel Small Molecule Designed To Overcome Cancer Drug Resistance.